AI assistant
AVACTA GROUP PLC Director's Dealing 2020
7507_dirs_2020-10-22_3ce839c6-eaa5-43b4-ba37-7eb1c3978a1f.html
Director's Dealing
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information 
RNS Number : 9550C
Avacta Group PLC
22 October 2020
22 October 2020
Avacta Group plc
("Avacta" or "the Group" or "the Company")
Director/PDMR Shareholding
Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, has today been informed that Alastair Smith, CEO, has sold 248,543 ordinary shares of 10p each ("Ordinary Shares") at an average price of 180.28 pence per share ("Sale"). The proceeds of the Sale will be used to part-fund the purchase of a primary residence for Dr. Smith and his family.
Following the Sale, Dr. Smith will have 431,100 Ordinary Shares and 5,908,525 options over Ordinary Shares, representing 2.5% of the issued share capital.
The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.
For further information from Avacta Group plc, please contact:
| Avacta Group plc | Tel: +44 (0) 844 414 0452 | |
| Alastair Smith, Chief Executive Officer | www.avacta.com | |
| Tony Gardiner, Chief Financial Officer | ||
| finnCap Ltd (Nominated Adviser and Joint Broker) | Tel: +44 (0) 207 220 0500 | |
| Geoff Nash / Giles Rolls - Corporate Finance Tim Redfern, Sunila de Silva - ECM |
www.finncap.com | |
| Stifel Nicolaus Europe Limited (Joint Broker) | Tel: +44 (0) 207 710 7600 | |
| Nicholas Moore / Nick Adams / Fred Walsh / Ben Maddison | www.stifel.com | |
| Yellow Jersey PR (Financial Media and IR) | Tel: +44 (0) 203 004 9512 | |
| Sarah Hollins / Henry Wilkinson | [email protected] | |
| Zyme Communications (Trade and Regional Media) | Tel: +44 (0) 7787 502 947 | |
| Katie Odgaard | [email protected] | |
About Avacta Group plc - www.avacta.com
Avacta is developing novel cancer immunotherapies combining its two proprietary platforms - Affimer® biotherapeutics and pre|CISION™ tumour targeted chemotherapy. With this approach, the Company aims to address the lack of a durable response to current immunotherapies experienced by most patients. The Company's therapeutics development activities are based in Cambridge, UK.
The Company benefits from near-term revenues generated from Affimer reagents for diagnostics, bioprocessing and research, through a separate business unit based in Wetherby, UK.
The Affimer platform is an alternative to antibodies derived from a small human protein. Despite their shortcomings, antibodies currently dominate markets worth in excess of $100 billion. Affimer technology has been designed to address many of these negative performance issues, principally: the time taken, and the reliance on an animal's immune response, to generate new antibodies; poor specificity in many cases; large size and cost.
Avacta's pre|CISION targeted chemotherapy platform, releases active chemotherapy only in the tumour, thereby limiting systemic exposure and damage to healthy tissues, and thereby improving the overall safety and therapeutic potential of these powerful anti-cancer treatments.
By combining these two platforms the Company is building a wholly owned pipeline of novel cancer therapies with the aim of creating effective treatments for all cancer patients including those who do not respond to existing immunotherapies. Avacta expects to take its first drug, a pre|CISION targeted form of the standard-of-care doxorubicin, into the clinic in early 2021.
Avacta has established drug development partnerships with pharma and biotech, including with Moderna Therapeutics Inc., a deal with LG Chem worth up to $400 million, a partnership with ADC Therapeutics to develop Affimer drug conjugates and has established a joint venture in South Korea with Daewoong Pharmaceutical focused on cell and gene therapies incorporating Affimer immune-modulators. Avacta actively seeks to license its proprietary platforms in a range of therapeutic areas.
Avacta diagnostics business unit works with partners world-wide to develop Affimers for evaluation by those third parties with the objective of establishing royalty bearing license deals. The Company is also developing a small in-house pipeline of Affimer-based diagnostic assays for licensing.
To register for news alerts by email go to www.avacta.com/investor-news-email-alerts
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1.
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Alastair Smith
2.
Reason for the Notification
a)
Position/status
Chief Executive Officer
b)
Initial notification/Amendment
Initial notification
3.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Avacta Group Plc
b)
LEI
2138009U3EG31OPMGH36
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the Financial instrument, type of instrument
Ordinary Shares
Identification code
GB00BYYW9G87
b)
Nature of the transaction
Sale of Ordinary Shares
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| 180.28 pence | 248,543 |
d)
Aggregated information:
· Aggregated volume
· Price
As above
e)
Date of the transaction
21 and 22 October 2020
f)
Place of the transaction
London Stock Exchange
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHKKBBQBBDDOKB